Survival protein a potential new target for many cancers

Researchers from the Walter and Eliza Hall Institute in Melbourne, Australia, have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells. Credit: Walter and Eliza Hall Institute of Medical Research

Walter and Eliza Hall Institute researchers have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells.

The discovery offers hope for treating many types of cancer that are driven to grow and spread through the actions of a cancer-causing protein called MYC.

Up to 70 per cent of human cancers, including many leukaemias and lymphomas, have unusually high levels of MYC, which causes in by forcing them into abnormally rapid growth.

Dr Gemma Kelly, Dr Marco Herold and Professor Andreas Strasser from the Walter and Eliza Hall Institute in Melbourne, Australia, led a research team investigating how cells with high levels of MYC stay alive and grow. They discovered that lymphomas that have high levels of MYC cannot survive long-term without a protein called MCL-1 which makes cells long-lived. Their research is published this week in the journal Genes & Development.

Dr Kelly said the research built on more than three decades of work at the institute into how MYC drives cancer development and how the survival of normal and is regulated. "For many years we have known that proteins from the BCL-2 protein family enhance cell survival and cooperate with MYC to accelerate the development of cancer," she said. "Until now, it was not known which specific BCL-2 family protein was most important for the survival and growth of MYC-driven cancers.

This video is not supported by your browser at this time.
Researchers from the Walter and Eliza Hall Institute in Melbourne, Australia, have discovered a promising strategy for treating cancers that are caused by one of the most common cancer-causing changes in cells. Credit: Walter and Eliza Hall Institute of Medical Research

"We discovered that with high levels of MYC can be killed by disabling a protein called MCL-1. Excitingly, when compared with healthy cells, the lymphoma cells were considerably more sensitive to a reduction in MCL-1 function. This suggests that in the future medicines that block MCL-1 could be effective in treating cancers expressing high levels of MYC with tolerable side-effects on the body's normal cells," she said.

Professor Strasser said the finding was exciting as there was hope that MCL-1 inhibitors may soon be available for clinical use. "MCL-1 is found at high levels in a number of and also many solid tumours, so there has been a strong drive to develop potential anti-cancer compounds that target MCL-1," he said.

"Anti-cancer agents that target the protein BCL-2, which is closely related to MCL-1, are already showing promise in clinical trials, including some held in Melbourne. We are hopeful that inhibitors of MCL-1 will soon become available for clinical testing. We will be very interested in determining whether these compounds could be used to treat MYC-driven cancers," Professor Strasser said.

Related Stories

Study identifies protein essential for normal heart function

Jun 17, 2013

A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, ...

Lymphoma therapy could deliver a double punch

Apr 30, 2012

B cell lymphomas are a group of cancers of that originate in lymphoid tissue from B cells, the specialized immune cell type that produces antibodies. The development of B cell lymphoma is associated with several known genetic ...

Protein may represent a switch to turn off B cell lymphoma

May 07, 2012

Researchers studying the molecular signals that drive a specific type of lymphoma have discovered a key biological pathway leading to this type of cancer. Cancerous cells have been described as being "addicted" to certain ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.